Jose Maria Fernandez Sousa-FaroPresident of PharmaMarone of the main Spanish pharmaceutical companies, appears in the investigation of the false vaccinated against Covid-19 carried out by the National Police, as CASO ABIERTO, the investigation and events channel of Prensa Ibérica, has learned.
The Jenner operation investigates the inclusion of 2,200 people, some of them very well known, in the National Immunization Registry in exchange for money. In the list of possible clients of the plot sent to the courts numbers 3 and 19 of Madrid appears Fernández Sousa. Sources in the case explained that the 76-year-old businessman was included in the lists drawn up by the plot to reflect that he had received the “third dose” of the vaccine.
Health approved in October the third dose for those over 70 years of age. Police investigations reveal that the plot was active and registered the 2,200 “false vaccinated” from the end of September 2021 to January 2022.
Fernández-Sousa has not been called to testify in the police, as was the case with the singer Omar Montes and others involved. He will be summoned by one of the two courts investigating the case, like the rest of the people included in the lists that have been discovered later, according to sources in the case. Consulted by OPEN CASE, PharmaMar company sources close to its president declined to comment. about this issue.
Fernández-Sousa is Professor of Biochemistry and founded PharmaMar in 1986. He has been in the pharmaceutical industry for more than 35 years and was a member of the boards of directors of Antibióticos, Penibérica, Pescanova and Cooper-Zeltia, among other companies. The company he chairs, PharmaMar, is one of the main Spanish pharmaceutical companies and emerged from the absorption of Zeltia in 2015. In 2021 he obtained profits of 92.82 millionand in the first quarter of this year it won 22 million euros, according to their own data.
PharmaMar is listed on the Ibex-35 and is dedicated to drug research obtained from marine resources to combat different types of cancer and Alzheimer’s. On its website, the company defines itself as “a company focused on oncology and committed to research and development that is inspired by the sea for the discovery of molecules with antitumor activity.”
A drug against covid
Among other drugs, PharmaMar markets Aplidin for myeloma patients multiple. This drug is now being tested, in the trial phase and pending authorization from the Ministry of Health, to treat precisely covid patients.
Last March, the president of PharmaMar assured in an interview with The Spanish what had suffered from coronavirus and that he had been treated with his company’s drug “with positive results”.